葡萄糖剥夺的肿瘤微环境激活 AMP 活化蛋白激酶驱动过继转移的 T 辅助 9 细胞衰老
Glucose-deprived tumor microenvironment activates AMP-activated protein kinase to drive adoptively transferred T helper 9 cell senescence.
辅助性T细胞9(Th9)细胞在针对实体瘤的过继细胞治疗(ACT)中显示出前景。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity.
Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
T细胞作为细胞疗法用于治疗晚期癌症已为许多患者带来临床获益,并推动了癌症研究领域的发展。然而,目前的细胞疗法对大多数患者并非治愈性,尤其是在实体瘤患者中,其未来能否广泛而有效地应用仍有待观察。近期研究已开始阐明调控癌症患者细胞疗法疗效的关键因素,包括T细胞干性以及有效靶向肿瘤抗原和克服肿瘤异质性的能力。在本综述中,我们讨论了临床有效抗癌T细胞疗法的关键特性,以及改善T细胞特征以增强实体瘤临床疗效的策略。
The administration of T cells as cellular therapy against advanced cancers has brought clinical benefit to many patients and has progressed the field of cancer research.
However, current cell therapy treatments are not curative in most patients, particularly in those with solid tumors, and it remains to be seen how broadly and efficaciously they may be applied going forward.
Recent research has begun to elucidate key factors that regulate the efficacy of cell therapy in cancer patients, including T cell stemness and the ability to effectively target tumor antigens and overcome tumor heterogeneity. In this review, we discuss key properties of clinically effective anti-cancer T cell therapies along with strategies to improve T cell characteristics to augment clinical efficacy in solid tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。